ibrutinib resistance-mechanisms and options in cll
Published 7 years ago • 3.3K plays • Length 29:14Download video MP4
Download video MP3
Similar videos
-
20:43
venetoclax resistance: mechanisms and treatment options
-
25:38
cll: chemotherapy and ibrutinib based regimens
-
23:08
ibrutinib resistance: is it predictable? what to do?
-
21:19
cll: sequencing monotherapy vs. combination therapy
-
14:12
abstract: single-agent ibrutinib 420mg induces durable responses in patients with cll
-
27:18
novel treatment options in cll
-
6:30
cll whiteboard #1: introduction & mechanisms of action of bcr signaling inhibitors
-
21:42
update on btk inhibitors for cll: ibrutinib pus the new kids on the block: are they better?
-
27:28
risk assessment in cll treatment
-
25:09
cll: long-term updates on ibrutinib and idelalisib
-
10:21
mechanisms of ibrutinib resistance in chronic lymphocytic leukemia
-
1:42
deciphering ibrutinib resistance in chronic lymphocytic leukemia
-
20:40
cll: treatment for btki progressors
-
35:31
cll: btk inhibitors in hematologic oncology pathways - pathway-guided choices
-
21:31
bcr inhibitors in cll and lymphoma
-
16:58
chronic lymphocytic leukemia: treatment options for btki progressors
-
22:08
role of chemotherapy in cll management
-
19:42
treatment options for the young cll patient with deletion 17p: do they need a different approach?
-
24:22
highlight of cll-related 2016 fda approvals: venetoclax